TICKERNERD
Menu
VRDNVRDNHealthcare · Biotechnology

VRDN Stock Forecast: Viridian Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$24
−0.86% on the day

The 17 Wall Street analysts covering Viridian Therapeutics, Inc. hold a median 12-month price target of $36 — +46.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 44 of 100 as at 22 Aug 2026 — in the lower half.

Market cap
$2.8B
Ticker Nerd rank
44 / 100
Median analyst target
$36
Analysts covering
17
Total return, dividends reinvested
1W
+10.0%
1M
+26.6%
YTD
−21.9%
1Y
+34.8%
From 52W high
−28.1%
From 52W low
+82.6%
$13
$34
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VRDN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Viridian Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
44 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
90
Volatility
80
Quality
56
Momentum
54
Value
53
Accruals
50
Revisions
45
Size
32
Issuance
7

Growth (90): Sales and profits are climbing, and climbing faster than before.

Issuance (7): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VRDN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VRDN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50Oct 25Jan 26Apr 26Jul 26VRDNHigh $50Median $36Low $22

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says17 analysts
17 Buy0 Hold0 Sell
Low $22Median $36High $50

The green dot is the last close — the median target sits +46.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
7 Aug 2026RBC CapitalMaintainsOutperform$35 → $36
7 Aug 2026Truist SecuritiesMaintainsBuy$38 → $39
30 June 2026NeedhamMaintainsBuy—
30 June 2026NeedhamMaintainsBuy$32 → $34
30 June 2026RBC CapitalMaintainsOutperform$34 → $35
30 June 2026RBC CapitalMaintainsOutperform—
30 June 2026Truist SecuritiesMaintainsBuy$35 → $38
30 June 2026Truist SecuritiesMaintainsBuy—
30 June 2026WedbushMaintainsOutperform—
30 June 2026WedbushMaintainsOutperform$32 → $43
29 June 2026NeedhamReiteratesBuy$32
29 June 2026NeedhamReiteratesBuy—
29 June 2026Wells FargoUpgradeOverweight—
29 June 2026Wells FargoUpgradeOverweight$20 → $31
15 May 2026Evercore ISI GroupMaintainsOutperform—
6 May 2026RBC CapitalMaintainsOutperform—
5 May 2026NeedhamReiteratesBuy—
21 Apr 2026Truist SecuritiesMaintainsBuy—
8 Apr 2026WedbushMaintainsOutperform—
7 Apr 2026Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VRDN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

VRDN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
7
Fundamentals

Viridian Therapeutics, Inc. (VRDN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−7.3×

Cheaper than 91% of US stocks

Price / sales
38.7×

Cheaper than 6% of US stocks

Price / book
4.9×

Cheaper than 22% of US stocks

EV / EBITDA
−5.2×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
278.7%

Higher than 97% of US stocks

Earnings growth (YoY)
278.7%

Higher than 92% of US stocks

Gross margin
—
Operating margin
−44460.6%

Higher than 1% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−65.7%

Higher than 18% of US stocks

Return on assets
−30.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

VRDN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VRDNViridian Therapeutics, Inc.$2.8B
44
ATAIAtai Beckley, Inc.$2.7B
28
NRIXNurix Therapeutics, Inc.$2.7B
45
TRVITrevi Therapeutics, Inc.$2.5B
54
PGENPrecigen, Inc.$2.5B
82
RAREUltragenyx Pharmaceutical, Inc.$2.5B
49
PHVSPharvaris NV$2.5B
42

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Viridian Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VRDN news & analysis

Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results

Business Wire · 6 Aug 2026positive

Viridian Therapeutics, a biotechnology company focused on autoimmune and rare diseases, reported recent business highlights and financial results for the second quarter ended June 30, 2026. The company noted encouraging early indications from the recent launch of Lumvoa as it transitions into a commercial-stage company.

Why it matters — VRDN watchers would care because this marks an early update on the commercial launch of the company's medicine, Lumvoa, reflecting its transition into a commercial-stage business.

FAQ

Frequently asked questions about VRDN stock

What is the VRDN stock price forecast for 2026-2027?

The 17 Wall Street analysts covering Viridian Therapeutics, Inc. have a median 12-month price target of $36, with estimates ranging from $22 to $50. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VRDN stock a buy right now?

Of the 17 analysts covering Viridian Therapeutics, Inc., 17 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Viridian Therapeutics, Inc. 44 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VRDN?

As at 22 Aug 2026, Viridian Therapeutics, Inc. ranks 44 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (90 of 100).

Will VRDN stock go up?

No one can know that. What the data says: the median 12-month target from 17 analysts implies +46.2% from the last close, and Ticker Nerd's factor model ranks Viridian Therapeutics, Inc. 44 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VRDN stock forecast for 2030?

No analyst covering Viridian Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VRDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $22 to $50 over the next 12 months.

How has VRDN stock performed over the past year?

Viridian Therapeutics, Inc. returned +34.8% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Viridian Therapeutics, Inc. do?

Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED).

What is the latest news on VRDN?

The most recent item we track (Business Wire, 6 Aug 2026): "Viridian Therapeutics Highlights Recent Business Progress and Reports Second Quarter 2026 Financial Results". Viridian Therapeutics, a biotechnology company focused on autoimmune and rare diseases, reported recent business highlights and financial results for the second quarter ended June 30, 2026. The company noted encouraging early indications from the recent launch of Lumvoa as it transitions into a commercial-stage company.

Company

About Viridian Therapeutics, Inc.

Viridian Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing best-in-class medicines for patients with autoimmune and rare diseases, particularly thyroid eye disease (TED). The company leverages expertise in antibody discovery and protein engineering to create differentiated therapeutic candidates targeting validated disease mechanisms. Its lead programs include veligrotug, a humanized monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R) administered intravenously, currently in Phase 3 clinical trials (THRIVE and THRIVE-2) for active and chronic TED. Viridian is also advancing elegrobart (formerly VRDN-003), a next-generation subcutaneous IGF-1R antibody with half-life extension technology, in ongoing Phase 3 trials (REVEAL-1 and REVEAL-2) for TED. Additionally, the company develops an anti-thyroid-stimulating hormone receptor (TSHR) program for TED and Graves' disease, along with neonatal Fc receptor (FcRn) inhibitors such as VRDN-006 and VRDN-008 for multiple autoimmune conditions. Headquartered in Waltham, Massachusetts, and founded in 2006, Viridian Therapeutics plays a key role in addressing unmet needs in rare autoimmune therapies through innovative antibody-based treatments.

CEO Mr. Stephen F. Mahoney J.D., MBA · 252 employees · United States · https://www.viridiantherapeutics.com